Here, we provide proof of concept of using adoptive therapy with CD4+CD25+CD127low UCB-Tregs for the treatment of LN by decreasing systemic and renal inflammation, and overall disease burden as shown by a decrease in anti-dsDNA Ab and improvement in albuminuria. Here, CD4 is linked to lobular neoplasia.